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Abstract
ErbB3 has been widely implicated in treatment resistance, but its role as a primary treatment target is less clear.
Canonically ErbB3 requires EGFR or ErbB2 for activation, whereas these two established treatment targets are thought
to signal independently of ErbB3. In this study, we show that ErbB3 is essential for tumor growth of treatment-naive
HNSCC patient-derived xenografts. This ErbB3 dependency occurs via ErbB3-mediated control of EGFR activation and
HIF1α stabilization, which require ErbB3 and its ligand neuregulin-1. Here, we show that ErbB3 antibody treatment
selects for a population of ErbB3-persister cells that express high levels of the transmembrane protein Trop2 that we
previously identiﬁed as an inhibitor of ErbB3. Co-treatment with anti-ErbB3 and anti-Trop2 antibodies is synergistic and
produces a greater anti-tumor response than either antibody alone. Collectively, these data both compel a revision of
ErbB-family signaling and delineate a strategy for its effective inhibition in HNSCC.

Introduction
Head and neck squamous cell cancer (HNSCC) is a
collection of diseases arising from the mucosal surfaces of
the oral cavity, oropharynx, nasopharynx, hypopharynx,
and larynx. With the exception of oropharyngeal cancers,
which are now commonly caused by human papilloma
virus, and nasopharyngeal cancers, which are often caused
by Epstein-Barr virus, most of these tumors are smoking
related1–3. Tobacco smoke produces a signiﬁcant mutational burden in smoking related cancers such as HNSCC
and other aerodigestive tumors, and is presumed to be
responsible for transformation4–6. However, similar to
other smoking related tumors, HNSCC sequencing efforts
have revealed that mutations are often scattered
throughout the genome, and the number of high-
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frequency actionable mutations (i.e., therapeutically targetable) is limited. This situation lies in contrast to virally
related oropharynx cancer, where the catalytic unit of PI3
kinase is mutated in approximately thirty percent of
cases7–9. Recurrent disease after curative therapy may be
associated with an increasing set of mutational events, but
the magnitude of these changes remains to be extensively
investigated10, and validated treatment targets are in great
need for HNSCC.
Epidermal growth factor receptor (EGFR) is the only
validated treatment target in HNSCC, and it is the most
commonly overexpressed oncogene in HNSCC11. Targeting EGFR with Cetuximab in combination with
radiation increases cure rates by ten percent, and prolongs
survival in metastatic disease12,13. The other ErbB family
members are thought to be involved in HNSCC but only
preliminary in vivo investigations of family targeting have
been reported14,15. ErbB2 (aka HER2) is ampliﬁed in
HNSCC at a very low frequency and ErbB3 (aka HER3),
the kinase-dead member of the family, is neither mutated
nor ampliﬁed in this disease11. ErbB3 has gained attention
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as a common mechanism of resistance to EGFR-targeted
therapies16–18. Its activation is dependent on heterodimerization with EGFR or ErbB2, a requirement that lies
in contradistinction to the independence of EGFR, for
which homodimerization is sufﬁcient to elicit its potent
tyrosine kinase activity. However, once ErbB3 heterodimerizes, its six PI3 kinase docking sites can potently
drive the PI3 kinase pathway rendering tumors resistant
to EGFR-targeted therapies and other conventional
agents.
Most pre-clinical studies implicate ErbB3 upregulation
in the context of drug resistance16,17,19–21 rather than
tumorigenesis. Mouse modeling has produced conﬂicting
results in terms of an essential role for ErbB3 in tumor
initiation, and the function of ErbB3 appears to be
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dependent on tissue and initiating oncogene22–24. Only in
the case of ErbB3 mutation, which is restricted to a small
percentage of gastrointestinal carcinomas, has this
receptor been found to be intrinsically oncogenic25.
Therapeutic targeting of ErbB3 in pre-clinical experiments also reveals equivocal results in terms of the
anti-tumor and anti-proliferative efﬁcacy of ErbB3
blockade. In HNSCC (and several other tumors),
antibody-mediated ErbB3 targeting has been most potent
when combined with EGFR or other receptor tyrosine
kinase inhibition26–32. Moreover, a recent clinical study of
combined EGFR and ErbB3 antibodies failed to show
improved efﬁcacy compared to single EGFR inhibition
with cetuximab33. Therefore, as an EGFR-driven tumor,
the role of ErbB3 in HNSCC is somewhat unclear.

Fig. 1 Description of patient-derived xenografts and their sensitivity to anti-ErbB3 antibody. a The table shows the derivation of the models
used in the study. b Growth curves of patient-derived xenografts treated with ﬁve weeks of anti-ErbB3 antibody. Tumors were allowed to grow to
150 mm3 prior to treatment for ﬁve weeks. Forty-eight hours after the 5th week residual tumor nodules were harvested. n = 10 mice per group.
Differences in growth between treated and untreated mice were signiﬁcant to P < 0.0001 (ANOVA) in all experiments
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Fig. 2 Assessment of residual nodules remaining after ErbB3 antibody treatment of mice harboring PDX tumors. Hematoxylin and eosin
stained tumor sections show varying degrees of cellularity in residual tumor nodules post-anti-ErbB3 antibody treatment. Shown are representative
examples of tumor nodules harvested from mice bearing UW-SCC22, UW-SCC31, and UW-SCC34. In some nodules, very few or no cells were
identiﬁed (UW-SCC31), whereas the degree of cellularity varied dramatically in other nodules

We previously identiﬁed Trop2 as an inhibitor of ErbB3.
Trop2 is a multi-functional transmembrane protein with
diverse signaling properties29,34–37. We reported that
Trop2 binds the ErbB3-ligand neuregulin-1, blocking its
cleavage and suppressing ErbB3 activation. RNAimediated Trop2 loss in HNSCC cell lines not only triggered ErbB3 hyperactivation, but resulted in sensitivity to
anti-ErbB3 antibodies. These ﬁndings led us to hypothesize that low Trop2 expression is required for optimal
sensitivity to anti-ErbB3 antibodies in HNSCC; however,
most human cancers show heterogeneous Trop2
Ofﬁcial journal of the Cell Death Differentiation Association

expression, rendering this conclusion uncertain. Following on this work, in this report we use a panel of patientderived xenograft models (PDX) and their cellular derivatives (conditionally reprogrammed cells, or CRCs38) to
show that ErbB3 is an essential component of the tumor
growth machinery in HNSCC. This essential function
stems from a fundamental role for ErbB3 in HNSCC
tumorigenesis, namely, an unexpected requirement for
neuregulin and ErbB3 for maximal EGFR signaling. We
also elucidate a novel therapeutic strategy involving coinhibition of ErbB3 and its inhibitor, Trop2.

Redlich et al. Cell Death and Disease (2018)9:5

Results
HNSCC patient-derived xenografts are broadly sensitive to
anti-ErbB3 antibody treatment

HNSCC is widely considered to be an EGFR-driven
disease as its overexpression confers a poor prognosis39,
Cetuximab is active in this disease, and most cell lines and
many PDX models are sensitive to the growth inhibitory
properties of cetuximab40. Recently, high protein levels of
the kinase-dead family member ErbB3 and its ligand
neuregulin have been shown to correlate with a poor
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prognosis in HNSCC41. In prior work, we identiﬁed an
inhibitor of ErbB3 activation, the transmembrane protein,
Trop229 and showed that Trop2 depletion in HNSCC cell
line xenografts predicted hypersensitivity to antibodymediated ErbB3 inhibition. These data suggested that
tumors with low Trop2 levels would be optimal targets for
anti-ErbB3 antibodies. To further test this hypothesis, we
obtained established40 as well as developed additional
novel PDX models of HPV-negative HNSCC from multiple tumor subsites including oral cavity, oropharynx,

Fig. 3 Requirement for ErbB3 for optimal EGFR activation in vivo and vitro. a Tumor cell lysates obtained from tumor nodules containing
persister cells after 5 weeks of treatment of anti-ErbB3 antibody treatment shows reduced levels of p-EGFR (Y1068) in ErbB3-antibody-treated mice
compared to vehicle treatment. b Representative immunoblots of protein lysates from conditionally reprogrammed cells (CRCs) from four PDX
models show reduced levels of p-EGFR after six days of incubation with anti-ErbB3 antibody (n = 3) or c three days after transient siRNA-mediated
knockdown of ErbB3 (n = 3) or d neuregulin-1 (n = 3). Antibodies to both Y1068 and Y1045 were used. Relative decreases in phosphoprotein levels in
control vs. experimental groups were quantiﬁed by photodensitometry after normalization to total EGFR or ErbB3. Squamous cells were separated
from Swiss 3T3 feeder cells by differential trypsanization prior to preparation of protein lysates
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hypopharynx, and larynx (Fig. 1a). We previously
observed that a subset of HNSCC tumors exhibit very low
Trop2 expression, but most HNSCC tumors show heterogeneous expression at the cellular level when assessed
by immunohistochemistry42. Our panel of PDX models
also showed heterogeneous Trop2 staining, which
mimicked most primary HNSCC tumors that we have
examined (Supplementary Fig. 1 and see Zhang et al.42)
Using these models, we carried out a series of ErbB3
antibody treatment experiments. The six PDX models
were permitted to grow to approximately 150 mm3 in
nude mice (n = 10 per cohort) and then treated with an
anti-ErbB3 antibody (Genentech) intraperitoneally using
our established dosing schedule42. All six models showed
a signiﬁcant tumor response to treatment (p < 0.0001 for
all). The tumors in three models (Hoc6, 4817 and 617)
were consistently eradicated after treatment while in three
other models (UW-SCC22, UW-SCC31, UW-SCC34),
growth arrest was achieved (Fig. 1b). Histologic assessment of residual tumors demonstrated persistence of
viable cells (Fig. 2). To conﬁrm the activity was not due to
a non-speciﬁc effect, mice bearing Hoc6 tumors (n = 4
per group) were treated with a second anti-ErbB3 antibody, mm-121 (Merrimack). Again, a signiﬁcant antitumor effect was seen (Supplementary Fig. 2). While the
activity of Cetuximab is complex, and is well established
to involve both signaling and immunologic mechanisms,
neither of the ErbB3 antibodies possess immunologic
activity19,26 suggesting that antibody-mediated ErbB3
inhibition was sufﬁcient to suppress growth of HNSCC
PDXs established from multiple anatomic subsites.
EGFR requires ErbB3 for maximal activation in HNSCC PDX
and CRC models

We determined whether ErbB3 antibody treatment
would inﬂuence levels of EGFR activation due to the
generally accepted ﬁnding that HNSCC is an EGFRdriven disease. We harvested cells from residual tumor
nodules from mice treated with ErbB3 antibody for ﬁve
weeks and measured levels of activated EGFR in residual
tumor cells (i.e., persister cells). Levels of activated EGFR
measured by phospho-speciﬁc antibodies declined both in
absolute terms and relative to total EGFR (Fig. 3a). In
some tumor samples, total EGFR was observed to be
increased after anti-ErbB3 antibody treatment (Fig. 3a).
We conﬁrmed that EGFR protein is only being measured
in the tumor, as immunohistochemistry using an EGFR
antibody cross-reactive to mouse and human in both
untreated and ErbB3-antibody-treated tumors showed
that only the HNSCC tumor cells and not the stroma
express EGFR (Supplementary Fig. 3). Next, we sought to
determine whether we could detect an effect of ErbB3
inhibition on EGFR activity in vitro, using patient-derived
tumors as opposed to established cell lines. We adapted a
Ofﬁcial journal of the Cell Death Differentiation Association
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culture system referred to as CRCs that has been harnessed to study targeted therapy sensitivity of primary
tumor cells43. In this system, primary tumor cells are
passaged on a layer of irradiated Swiss NIH/3T3 cells and
harvested with differential trypsinization38. When CRCs
from two patient-derived xenografts and two CRC models
grown directly from a biopsy of the oral tongue were
exposed to the anti-ErbB3 antibody for six days, we
observed a similar decrease in EGFR activity and
increased expression of Trop2 (Fig. 3b). Investigation into
the unpredicted possibility that ErbB3 controls EGFR
activation was further undertaken by the use of siRNAs
against ErbB344. Ninety-six hours after transfection of
ErbB3 SMARTpool siRNAs, tumor cells from CRC cultures were harvested and again probed for levels of EGFR
activation, experiments which showed elevated levels of
Trop2 and reduced levels of p-EGFR even when ErbB3
was incompletely suppressed (Fig. 3c). To further
demonstrate a causal relationship between ErbB3 and
EGFR activation, we also transiently knocked down
neuregulin-1, the ErbB3 ligand, and again examined levels
of EGFR activation. In addition to suppressing ErbB3
activation and elevating Trop2 expression, incomplete
neuregulin-1 depletion signiﬁcantly reduced EGFR activation, consistent with the observed effects of the ErbB3
knockdown and ErbB3 antibody treatment (Fig. 3d).
These Trop2 results are consistent with our previously
published results ﬁnding Trop2 expression to be inversely
proportional to ErbB3. We also investigated the effect of
ErbB3 inhibition on ErbB2. Basal levels of ErbB2 were
found to be very low by both western blotting and
immunohistochemistry (Supplementary Figs. 4 and 5).
Moreover, we did not observe consistent changes in pErbB2 levels with ErbB3 inhibition (Supplementary
Figs. F4 and 5) suggesting that ErbB3 is not as tightly
linked to ErbB2 function as it is to EGFR. Collectively,
these data show for the ﬁrst time that a neuregulin-ErbB3
axis controls EGFR activation in HNSCC CRCs and PDX
models.
ErbB3 regulates HIF1α in HNSCC CRCs

When performing the ErbB3 loss of function experiments in vitro, no decrease in cell number or proliferation
was observed in anti-ErbB3-treated cells when compared
to control cells (Supplementary Fig. 6A, B). This lack of
efﬁcacy in vitro is similar to that observed with PI3 kinase
inhibition in other models and contexts (see Costa et al.45
and references therein). This suggested that
ErbB3 signaling is particularly important for aspects of
tumor growth related to the in vivo tumor microenvironment that are not required for in vitro growth. In
three-dimensional in vitro culture systems, ErbB3 has
been shown to be upregulated by HIF1α46, which is particularly important as tumors grow beyond their blood
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Fig. 4 ErbB3 is essential for increased HIF1α stabilization in HNSCC. a Protein lysates taken from larger ( ≥ 12 mm, n = 10) compared to smaller
( ≤ 6 mm, n = 3) tumors show that EGFR and ErbB3 are co-upregulated coincident with HIF1α stabilization in larger tumors. b Protein lysates from
conditionally reprogrammed cells (Hoc6) exposed to CoCl2 show that two-hour pre-treatment with anti-ErbB3 antibody (left panel, n = 3) but not
Cetuximab (right panel, n = 3) suppresses cobalt chloride-dependent HIF1α stabilization, which is maximal at three hours. Relative HIF1α levels in
control vs. treatment groups were quantiﬁed by photodensitometry after normalization to actin

supply and encounter a hypoxic environment. In addition,
in some contexts, EGFR promotes HIF1α stabilization
primarily through its ability to activate the PI3 kinaseAKT pathway (Heeg et al. and references therein47).
Therefore, we considered that the potent anti-tumor
effect exerted by the ErbB3 antibody observed in vivo may
also be related to a speciﬁc requirement for ErbB3 in
tumor growth under hypoxic conditions. To test this
possibility, we harvested PDX tumors from three of the
models when they were either relatively small (≤6 mm in
greatest diameter) or large (≥12 mm in greatest diameter),
and measured ErbB3 activation and HIF1α levels, in
addition to activated EGFR. Notably, ErbB3 and EGFR
showed synchronously increased activation coincident
with HIF1α stabilization in larger tumors (Fig. 4a. and
Supplementary Fig. 7). To more fully investigate the
relationship between ErbB3 in the HIF1α in the HOC6
CRC cultures, we used cobalt chloride (CoCl2) to mimic
the hypoxic environment and promote HIF1α stabilization. Short-term exposure to this salt increased HIF1α
Ofﬁcial journal of the Cell Death Differentiation Association

and a panel of other hypoxia-inducible genes (Supplementary Fig. 8). When cells were pre-treated with the
anti-ErbB3 antibody for two hours prior to the addition of
CoCl2, the accumulation of HIF1α was signiﬁcantly attenuated (Fig. 4b). Notably, Cetuximab treatment did not
reduce HIF1α levels, but actually increased its stability
(Fig. 4b, right panel). These results suggest that ErbB3 is
required not only for optimal EGFR activity, but is
essential for acute upregulation of HIF1α. Altogether, they
explain the efﬁcacy of ErbB3 inhibition in the PDX
models.
Upregulation of Trop2 in ErbB3-treated persister cells
results in ErbB3-Trop2 synergistic targeting

As we previously reported, Trop2 binds to neuregulin-1,
inhibiting its cleavage, and suppressing ErbB3 activation42. This observation explained the hypersensitivity to
ErbB3 antibodies caused by RNAi-mediated depletion of
Trop2 in HNSCC cell line xenografts that otherwise show
very low levels of ErbB3 activation. As such, when we

Redlich et al. Cell Death and Disease (2018)9:5
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Fig. 5 ErbB3 antibody treatment results in increased Trop2 levels. a Protein lysates from tumor nodules harvested from mice after 5 weeks of
anti-ErbB3 antibody treatment reveals increased levels of Trop2 in persister cells. b Right panels are photomicrographs of Trop2 staining in FaDu
tumor xenografts after ﬁve weeks of anti-ErbB3 antibody treatment; left panels show immunoblots from the same tumor xenografts. N = 5 per group.
Trop2 levels were quantiﬁed by photodensitometry and normalized to actin. c Synergistic activity of ant-Trop2 and anti-ErbB3 antibodies against UWSCC34 xenografts growing in mice. N = 5 per group

initiated ErbB3 treatment experiments in the PDX models, we expected to segregate ErbB3 sensitivity based on
high vs. low Trop2 expression. Instead, we found that
these models recapitulate the heterogeneity of Trop2
expression exhibited by most HNSCC human tumors (see
Zhang et al.42 and Supplementary Fig. 1) and they also
show low levels of ErbB3 expression by IHC (Supplementary Fig. 9). The data uncovered here suggests a more
complex biological relationship between ErbB3 and
Trop2. To gain a deeper understanding of this
Ofﬁcial journal of the Cell Death Differentiation Association

relationship, we asked whether ErbB3 antibody treatment
would inﬂuence Trop2 expression. We started by examining the effects of ErbB3 antibody treatment on Trop2
expression levels in the ErbB3-persister cells that we were
able to harvest post-ErbB3 treatment. In tumor material
successfully obtained from ErbB3-treated persister cells
from two PDX models, resistance to ErbB3 treatment was
associated with an increase in Trop2 protein expression
(Fig. 5a). We also examined the impact of ErbB3 treatment on Trop2 in a Trop2 low-expressing HNSCC cell
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line, FaDu. The tumor cells were implanted in mice (n = 5
tumors), allowed to grow to 150 mm3 and treated with the
antibody to ErbB3. After three weeks, residual tumors
were harvested and prepared for immunohistochemical
and protein analysis. ErbB3 treatment resulted in
increased Trop2 protein levels (Fig. 5b). These data led us
to consider that ErbB3 antibody treatment may sensitize
to treatment with anti-Trop2 therapeutics, which have
now entering clinical trials. When the Trop2 antibody
(Pﬁzer) was administered intraperitoneally on a weekly
schedule to UW-SCC34 tumors, growth arrest comparable to single ErbB3 antibody treatment was observed.
When the two antibodies were used simultaneously, they
produced an anti-tumor effect that was more pronounced
and synergistic compared to the observed single-agent
activity of either antibody alone (Fig. 5c). These data
indicate that co-inhibition of ErbB3 and Trop2 creates a
synthetic dependency of each molecule on the other one
resulting in a signiﬁcant therapeutic beneﬁt from combination treatment.

Discussion
In this study, we investigated the requirement for
ErbB3 in HNSCC. Targeting ErbB3 alone in a panel of
PDXs revealed unexpected single-agent activity. The
result was unexpected because numerous studies in
HNSCC and other cancer cell lines generally indicated
that co-targeting ErbB3 with EGFR or other pathways,
chemotherapy, or radiotherapy, was required to
yield a signiﬁcant beneﬁt from ErbB3 inhibition26,28–32. In
addition, ErbB3 is frequently upregulated by various
treatment strategies and as a result has more commonly
been implicated as a mediator of resistance to therapy
rather than an essential driver of tumorigenesis. Given the
EGFR overexpression in HNSCC, this disease is considered to be an EGFR-driven tumor. Notably, ErbB3 is
neither mutated, ampliﬁed, nor signiﬁcantly overexpressed in HNSCC. Our data suggest, however,
that ErbB3 is an essential component of the tumor growth
machinery in HNSCC and the molecular details
provided in this report offer some insight into why this is
the case.
EGFR is capable of autophosphorylation, and as such,
does not canonically require dimerization with ErbB2 or
ErbB348–50. In contrast, ErbB3 has been considered to be
kinase-dead (although recent evidence may eventually
overturn this idea50, and, therefore, requires a dimerization partner. Either EGFR or ErbB2 is considered essential
for the ability of ErbB3 to activate downstream signaling.
While neuregulin stimulation has been shown to result in
EGFR transactivation in cultured cells51, neither neuregulin nor ErbB3 have ever been shown to be essential for
the activity of EGFR. We observed that ErbB3-inhibited
patient-derived tumors and derivative cultured CRCs are
Ofﬁcial journal of the Cell Death Differentiation Association
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unable to maintain maximal EGFR signaling. This
diminution occurred whether ErbB3 activity was
decreased by ErbB3 antibody treatment, or siRNA to
ErbB3 or neuregulin-1. Altogether, the data suggest that
in HNSCC, full EGFR activation is dependent on the
ErbB3-neuregulin-1 axis, a hierarchy that has not been
previously demonstrated in any tumor type. These
data are also consistent with and provide a reason for
the observation that compared to other cancers,
HNSCC tumors have among the highest levels of
neuregulin-1. These levels increase in recurrent tumors
that arise after curative treatments with radiation and
chemotherapy52.
Another key ﬁnding identiﬁed in this report explains a
feature of PI3kinase signaling inhibition that has been
observed in several tumor models but not well understood, namely the lack of observed efﬁcacy of ErbB3
inhibition in vitro relative to the profound anti-tumor
effect in vivo. Other groups have reported a similar discordance with inhibitors of the PI3 kinase pathway45, but
this observation has not been explained experimentally.
This lack of in vitro efﬁcacy with concomitant in vivo
activity led us to consider a role for ErbB3 in responding
to the tumor microenvironment. In support of this idea,
we noted that as the PDXs grew in size they exhibited a
dramatic increase in total and activated EGFR, ErbB3, and
the hypoxia regulated transcription factor, HIF1α.
EGFR itself has been reported to drive HIF1α expression
in some systems53, but we did not observe any effect of
Cetuximab on HIF1α levels in controlled CoCl2 experiments. Interestingly, 3D tissue culture assays of HNSCC
cells have shown that linked HIF1α upregulates
ErbB346. Our data suggest that regulation may occur in
both directions, as suppression of ErbB3 signiﬁcantly
reduced the ability of CoCl2 -induced hypoxia signaling to
upregulate HIF1α. Collectively, these data point to ErbB3
as a mediator of signaling required for survival in the
hostile tumor microenvironment, a requirement that is a
likely source of the anti-tumor activity of anti-ErbB3
antibodies.
The lack of high-frequency actionable mutations in
HNSCC presents a barrier to the development of novel
targeted treatment approaches, particularly in smokingrelated disease which is a difﬁcult-to-treat group of
tumors with a high mortality rate. Despite extensive
genomic investigation, genetic alterations of molecular
drivers such as EGFR (other than PI3 kinase) have not
been identiﬁed in HNSCC4,5,11, and the lack of mutations
in HNSCC corresponds with the failure to ﬁnd genetic
addictions in this disease. The data presented here in this
report not only underscore the limitations of therapeutic
inhibition of non-genetically altered targets, but also
suggest that strategies to overcome these limitations are
within reach in some cases. While ErbB3 inhibition alone
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exerts potent anti-tumor activity, some “persister” cells
are able to survive and show upregulation of Trop2, the
negative regulator of ErbB342. The ability of dual targeting
of ErbB3 and Trop2 to more completely suppress
tumorigenesis suggests that ErB3 treatment creates a
novel dependency on Trop2. Therefore, the ErbB3-Trop2
interaction uncovered here provides a treatment possibility that is predicted to be highly effective and a model for
inhibiting other non-mutated (e.g., non-addicted) targets.
The extent to which dual inhibition will provoke a potent
addiction in patients should be tested formally in clinical
trials.

Materials and methods
Cell line maintenance—Hoc6, Hoc43, 4817, 8842

Swiss 3T3 ﬁbroblasts, aka feeder cells, at lower passage
number were trypsinized and collected as a cell pellet. The
cell pellet was irradiated at 30 Gray (3000 rad). After
irradiation, feeder cells were plated at 70–90% density in
complete Dulbecco's Modiﬁed Eagle Medium (DMEM)
media. Irradiated feeder cells were allowed to attach at
least three hours prior to plating CRC lines over feeder
cells in F media. F media: Complete DMEM 1x (DMEM—
Gibco # 11965-092; 10% FBS—Gibco #16140-071; 1% Lglutamine—Gibco # 25030-081; 1% Pen/Strep—Gibco #
15140-122); F-12 Nutrient Mix 1x—Gibco #11765-054;
25 microgram/milliliter (µg/ml) Hydrocortisone—Sigma
H-0888; 0.125 µg/ml EGF—Invitrogen #PHG0311L; 5
milligram/milliliter (mg/ml) Insulin—Sigma #I-5500; 11.7
microMolar (µM) cholera toxin—Sigma #C-8052. Cells
were grown more the 70% dense then split with differential trypsinization. Co-cultures were brieﬂy washed with
sterile phosphate-buffered saline (PBS) and incubated
with 0.05% trypsin solution at room temperature for 1–3
min (min). Flasks were gently tapped until all feeders
detached from substrate as conﬁrmed with close monitoring by phase microscopy. Detached cells were
removed by aspiration. Tightly adherent epithelial cells
were rinsed again with PBS, and then re-trypsinized with
0.25% at 37 °C for 3–5 min. Cells were dispersed into
single suspension with gentle pipetting, pelleted and
resuspended in F medium for passaging. Cell line FaDu
was maintained in DMEM/F12 media. DMEM/F12 media:
DMEM/F12—Gibco #11330–032; 10% FBS—Gibco
#16140-071; 25 µg/ml Hydrocortisone—Sigma H-0888;
1% Pen/Strep—Gibco # 15140-122.
Western blots analysis

For CRC cell line protein expression, Swiss 3T3 ﬁbroblasts were ﬁrst trypsinized off with 0.05% trypsin. Culture
plates were washed with buffer and cell pellets were collected with cell scrapers and lysed with standard RIPA
buffer supplemented with 1 milliMolar (mM) sodium
orthovanidate, 1 mM phenylmethylsulfonyl ﬂuoride, and
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protease inhibitor cocktail P8340 (Sigma-Aldrich). Cell
pellets were incubated on ice for twenty min with constant agitation, centrifuged for two min and supernatants
were collected. For xenograft tumor protein expression,
tumor chunks were homogenized using pestles and lysed
in RIPA buffer for 20 min before sonication, centrifugation for 10 min at 4 °C, and supernatant collection. Total
protein concentrations were determined by Quick Start™
Bradford Assay (BioRad).
Forty microgram of protein lysate were added per
sample, diluted in millipure H2O to 20 microliters (µl),
and diluted further with 5x sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) Loading
Buffer. Samples with boiled at 95 °C for 5 min and ran
through an SDS-PAGE gel. Samples were electrotransfered onto 0.2 µM polyvinylidene ﬂuoride membranes. Membranes were blocked with 5% milk in 1x PBS0.1% Tween20 for 30 min at room temperature. Primary
antibodies diluted in PBS-0.1% Tween20, 3% bovine
serum albumen, 0.02% sodium azide (NaN3) solution
were incubated overnight on a rocker at 4 °C. After primary antibody incubation, membranes were washed three
times in 1x PBS-0.1% Tween20 for 8 min each. Speciesspeciﬁc HRP conjugated secondary monoclonal antibodies were diluted in 5% milk in 1x PBS-0.1% Tween20
at a concentration of 1:5000 and incubated for 1 h at room
temperature. After secondary antibody incubation,
membranes were washed three times in 1x PBS-0.1%
Tween20 for 8 min each. SuperSignal West Femto Maximum Sensitivity Substrate (Thermo) was used for
visualization. Images were acquired using Chemidoc XRS
+ imaging system and Image Lab Software. Primary
antibodies used are as follows: anti-Phospho-EGFR
(Tyr1068) Cell Signaling Technology #3777, antiPhospho-EGFR (Tyr1045) Cell Signaling Technology
#2237, anti-EGFR Cell Signaling Technology #4267, antiPhospho-ErbB3 (Tyr1289) Cell Signaling Technology
#4791, anti-ErbB3 Cell Signaling Technology #12708,
anti-NRG1 R & D Systems AF-296-NA, anti-Actin SigmaAldrich A1978, anti-Tubulin Sigma-Aldrich T6199, antiHIF1α Abcam ab51608, and anti-Trop2 R & D Systems
AF650.
Anti-ErbB3 treatment in vitro with Dl3.6b and mm121

Irradiated Swiss 3T3 ﬁbroblasts were plated in 60 millimeter (mm) plates at 500,000 cells in 2 ml media. CRC
lines were plated on irradiated ﬁbroblasts 3–5 h later at
50,000 cells per well in CRC culture media. Twenty-four
hours following CRC culture splitting procedure, regular
F media (control samples) and Dl3.6b (100 µg/ml) or mm121 (170 µg/ml) supplemented F media (experimental
samples) was added. Following incubation at 37 °C for 72
h, fresh F media with and without anti-ErbB3 antibody
Dl3.6b (Genentec) or mm-121 (Merrimack) was added.
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Samples were incubated for another 72 h. Samples were
washed with PBS and Swiss 3T3 ﬁbroblasts were detached
with 0.05% Trypsin. Culture plates were washed with PBS
and cell pellets were collected with cell scrapers and lysed
with RIPA buffer.
Cell counting

Irradiated Swiss 3T3 ﬁbroblasts were plated in sixwell plates at 280,000 cells in 2 ml media. CRC lines
were plated on irradiated ﬁbroblasts 3–5 h later at
50,000 cells per well in CRC culture media. Twentyfour hour following CRC culture splitting procedure,
regular F media (control samples) or Dl3.6b (100 µg/
ml) supplemented F media (experimental samples) was
added. Following incubation at 37 °C for 72 h, fresh F
media with and without Dl3.6b was added. Samples
were incubated for another 72 h. Samples were washed
with PBS and Swiss 3T3 ﬁbroblasts were detached with
0.05% Trypsin/EDTA. CRC lines were detached with
0.25% Trypsin. Aliquots were diluted 1:2 with Trypan
Blue and a viable cell count was obtained using a
hemocytometer.
CoCl2

Irradiated Swiss 3T3 ﬁbroblasts were plated in 60 mm
plates at 500,000 cells in 2 ml media. CRC lines were
plated on irradiated ﬁbroblasts 3–5 h later at 50,000 cells
per well in CRC culture media. Cells were grown to 50%
conﬂuence, and then either anti-ErbB3 Dl3.6b (100 µg/ml)
or anti-EGFR Cetuximab (14 µg/ml) was added. CoCl2
was added for a ﬁnal concentration of 200 µM to
antibody-treated and control plates 2 h later. Samples
were collected following either three or six hours incubation. Irradiated ﬁbroblasts were trypsinized off, culture
plates were washed with buffer, and cell pellets were
collected with cell scrapers and lysed with RIPA buffer.
siRNA-mediated ErbB3 and NRG1 knockdowns

CRC cells (Hoc6, 4817, Hoc43, 8842) were transiently
transfected with ErbB3 siRNA (siErbB3; ON-TARGETplus, SMARTpool # L-003127; Dharmacon), siNRG1
(ON-TARGETplus, SMARTpool # L-004608; Dharmacon), or non-targeting siRNA (siNT; ON-TARGETplus
Non-targeting Pool, #D-001810; Dharmacon) using
Lipofectamine 2000 according to the manufacturer’s
instructions (Life Technologies).
Xenograft studies

Mouse xenograft experimental protocols were approved
by the Institutional Animal Care and Use Committee
(IACUC) at Washington University in St. Louis. Animals
were maintained and evaluated under pathogen-free
conditions following IACUC guidelines (St. Louis, MO).
Athymic nude mice (4 to 6-weeks-old females) were
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obtained from Jackson Laboratories (Bar Harbor, ME).
PDXs were surgically grafted in the ﬂanks of each mouse
utilizing sterile technique and follow up care. CRC tumor
xenografts were generated by separating off Swiss 3T3
feeder cells with 0.05% trypsin and washing with Dulbecco’s PBS, followed by 0.25% trypsin to produce a
suspension of CRC cells in media. In all, 2.0 × 106 cells in
media and 30% Matrigel (BD Biosciences) were injected
subcutaneously into both ﬂanks of each mouse. Tumors
were measured in length and width with calipers several
times per week and volumes were calculated using the
formula (length X width2)/2. Tumors were allowed to
reach an approximate volume of 150 mm3 before being
round-robined into treatment groups. Mice were treated
with intraperitoneal injections of anti-ErbB3 antibody
(Genentech) at 25 milligram/kilogram (mg/kg) weekly,
anti-Trop2 antibody (Pﬁzer) at 20 mg/kg weekly, the
combination of the two at the same dose and schedule, or
with PBS for negative control. Mice were sacriﬁced
according to IACUC approved protocol upon reaching
two centimeters diameter in one dimension or two days
after last treatment. Tumor material was harvested for
both protein analyses by western by snap freezing in
liquid nitrogen and histological studies by formalin
ﬁxation.
Histological studies

Tumor samples were ﬁxed in ten percent neutral buffered formalin for 24–48 h and embedded in parafﬁn wax
at the end of experiments. Sequential slices of each tumor
were transferred to charged microscope slides and samples were processed for Hematoxylin and Eosin and
protein expression (anti-Trop2 R & D Systems AF650
1:500). Samples were deparafﬁnized with two, ﬁve min
washes in xylenes. Samples were then rehydrated through
ethanol series. Heat-induced antigen retrieval was then
performed using either citric acid solution (H3300) or
basic EDTA solution (CTS013) according to primary
antibody recommendation utilizing a microwave. Primary
antibodies were diluted in antibody solution: PBS, 1%
normal donkey serum, 0.3% Triton X-100, and NaN3
0.0003% pH 7.4. Samples were incubated overnight with
primary antibody at 4 °C in moist chamber. The following
day, samples were washed three times with PBS for 5 min
each and incubated with species-speciﬁc biotinylated
secondary antibody for an hour at room temperature.
Samples were again washed three times with PBS and
then incubated with avidin-biotin HRP complex solution
(Vector) prepared 30 min before use for 30 min. Following
three, 5 min washes, samples were developed using diaminobenzidine substrate and counterstained with hematoxylin. Slides were then dehydrated through ethanol
series and sealed using xylene based solution. Histology
images were collected with Olympus BX51 microscope
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with Olympus DP70 camera using 4x, 20x, and 40x
objective lenses.
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